For example, it has been shown that RA variants are enriched specifically in Tregs and CD4+ T cells, whereas in SLE variants are mostly enriched in plasmacytoid dendritic cells and B cells—thus showcasing cellular context and possible future specific drug targets [184,185]. This evidence concerns the gene CD4 and rheumatoid arthritis.